FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read29 March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved…
Amivantamab Combo in EGFR Exon 20 NSCLC: PAPILLON Results Nicolas Girard, MD Non-Small Cell Lung Cancer 2 Mins Read8 By. Nicolas Rigard, MDDate. 11/20/2023In this interview, Nicolas Girard, MD, a medical doctor and professor of respiratory medicine at Versailles,…
EGFR Mutations: Amivantamab Combo in 1L NSCLC Non-Small Cell Lung Cancer 2 Mins Read4 By. Nicolas Girard, MD Date: 11/15/2023 In a significant development in the field of oncology, Nicolas Girard, MD, played a…
